PGR and Charcot-Marie-Tooth disease type 1A: Unfortunately, a clinical trial evaluating Ulipristal acetate, a selective progesterone receptor modulator, in CMT1A patients has been prematurely discontinued (Clinical trial N° NCT02600286) on the request of European and French regulatory agency due to serious liver injury in patients treated with ulipristal acetate in another unrelated clinical trial.